What is the history of Paroxysmal nocturnal hemoglobinuria?

Paroxysmal nocturnal hemoglobinuria (PNH) was first clinically characterized in the late 19th century, with its name evolving to reflect the observation that hemoglobinuria often occurred overnight. Today, Paroxysmal nocturnal hemoglobinuria is understood as a rare, acquired clonal hematopoietic stem cell disorder driven by somatic mutations in the PIGA gene, marking a shift from a misunderstood mystery to a condition manageable with targeted molecular therapies.

When and how was Paroxysmal nocturnal hemoglobinuria first described?

The clinical history of Paroxysmal nocturnal hemoglobinuria dates back to 1882, when German physician Paul Strübing provided the first detailed clinical description of the condition. He recognized that the dark-colored urine observed in his patients was caused by the presence of hemoglobin. Initially, the disease was often confused with other forms of hemoglobinuria. It was not until 1911 that the term "paroxysmal nocturnal hemoglobinuria" was coined by Enneking, formalizing the observation that the destruction of red blood cells—hemolysis—often seemed to occur during sleep, likely due to subtle changes in blood pH related to nocturnal hypoventilation.

How has our understanding of the disease evolved?

For decades, Paroxysmal nocturnal hemoglobinuria remained a diagnostic challenge. In the mid-20th century, researchers identified that the red blood cells of these patients were abnormally sensitive to the complement system, a part of the immune system. However, the precise molecular defect remained elusive until the 1990s. The breakthrough came with the discovery that patients with Paroxysmal nocturnal hemoglobinuria possess a somatic mutation in the PIGA gene. This mutation prevents the anchoring of certain protective proteins to the cell surface, leaving blood cells vulnerable to "friendly fire" from the body’s own complement system.

What were the major milestones in treatment?

The treatment landscape for Paroxysmal nocturnal hemoglobinuria has transformed from supportive care to precision medicine:

• Pre-1950s: Management was limited to blood transfusions and iron supplementation to combat anemia.


• 1950s–1990s: Corticosteroids and androgen therapy were used with limited success, often accompanied by significant side effects.


• 2007: The FDA approved eculizumab, the first complement inhibitor. This was a revolutionary milestone, as it allowed patients to stop chronic blood transfusions and significantly reduced the risk of life-threatening thrombosis.


• Modern Era: The development of newer, longer-acting complement inhibitors like ravulizumab and pegcetacoplan continues to improve the quality of life for the 162 members of our DiseaseMaps community and others globally.

How did modern genetics clarify the condition?

Modern genetic technology has corrected long-standing misconceptions about Paroxysmal nocturnal hemoglobinuria. It is now definitively classified as an acquired, not inherited, disorder. Genetic testing using high-sensitivity flow cytometry has become the gold standard for diagnosis, allowing clinicians to detect the size of the PNH clone—the percentage of blood cells lacking the protective proteins—with extreme precision. This shift has empowered physicians to tailor treatment based on the severity of the clone rather than relying on trial-and-error.

Next steps

• Consult a hematologist specializing in bone marrow failure syndromes or complement-mediated disorders.


• Join the Paroxysmal nocturnal hemoglobinuria support groups on DiseaseMaps.org to connect with others who have navigated this journey.


• Ask your specialist about the latest clinical trials regarding novel complement pathway inhibitors.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal nocturnal hemoglobinuria overview.


• Orphanet: Rare disease database entry for Paroxysmal nocturnal hemoglobinuria (ORPHA:408).


• Online Mendelian Inheritance in Man (OMIM): PIGA gene and PNH pathophysiology (#300818).


• Aplastic Anemia & MDS International Foundation: PNH treatment and research updates.